YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.26
+0.84 (+3.92%)
At close: 4:00PM EST

22.26 0.00 (0.00%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close21.42
Open21.42
Bid22.26 x 800
Ask30.00 x 900
Day's Range21.37 - 23.17
52 Week Range15.17 - 31.00
Volume38,181
Avg. Volume75,918
Market Cap761.152M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Y-mAbs Therapeutics to Present at PEGS Boston

    NEW YORK, Feb. 13, 2019 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?
    Simply Wall St.2 months ago

    What Kind Of Investor Owns Most Of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)?

    A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • GlobeNewswire2 months ago

    Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Dec. 13, 2018 -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and.

  • GlobeNewswire2 months ago

    Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the appointment of the molecular nuclear medicine executive, Dr. Gérard Ber, PhD to its board of directors, and the planned departure of Dr. Michael Buschle, PhD. The departure of Dr. Buschle and the appointment of Dr. Ber is effective December 11, 2018.

  • GlobeNewswire2 months ago

    Y-mAbs Therapeutics Announces FDA Clearance of IND for its Bispecific GD2 Antibody

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Investigational New Drug (“IND”) application for a humanized bispecific GD2 antibody. It is anticipated that a Phase 1/2 clinical trial will soon be initiated to begin screening patients with relapsed/refractory neuroblastoma, high grade osteosarcoma and other GD2(+) solid tumors, where patients have relapsed or refractory disease that is resistant to standard therapy.